DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results [Yahoo! Finance]
DiaMedica Therapeutics Inc. (DMAC)
Last diamedica therapeutics inc. earnings: 11/13 04:12 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Preeclampsia Phase 2 Investigator-sponsored Trial Beginning in Q4 2024 with Proof-of-Concept Results Targeted for First Half 2025 Completed $12 Million Private Placement, Extending Cash Runway Into Q3 2026 MINNEAPOLIS, August 07, 2024 BUSINESS WIRE )--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today provided a business update and financial results for the quarter ended June 30, 2024. Management will host a conference call Thursday, August 8, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and second quarter 2024 financial results. ReMEDy2 Phase 2/3 AIS Clinical Developments Progress continues with site activation activities accelerating. As part of this, DiaMedica has selected and prioritized fifteen research centers in the United States that are anticipated to be top enrollment centers. DiaMedica anticipates these top fifteen ce
Show less
Read more
Impact Snapshot
Event Time:
DMAC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DMAC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DMAC alerts
High impacting DiaMedica Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
DMAC
News
- DiaMedica Therapeutics Upcoming Conference ParticipationBusiness Wire
- DiaMedica Therapeutics Inc. (NASDAQ: DMAC) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $6.00 price target on the stock.MarketBeat
- DiaMedica Therapeutics Inc. (DMAC) Q2 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial ResultsBusiness Wire
- Are Medical Stocks Lagging DiaMedica Therapeutics (DMAC) This Year? [Yahoo! Finance]Yahoo! Finance
DMAC
Earnings
- 8/7/24 - Beat
DMAC
Sec Filings
- 8/7/24 - Form 8-K
- 8/7/24 - Form 10-Q
- 7/19/24 - Form EFFECT
- DMAC's page on the SEC website